Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trialsMassimo Gentile, Pellegrino Musto, Enrica Antonia Martino et al.|Haematologica|2023Cited by 19
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trialsEnrica Antonia Martino, Pellegrino Musto, Salvatore Palmieri et al.|Hematological Oncology|2024Cited by 7
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemiaFortunato Morabito, Massimo Gentile, Giovanni Tripepi et al.|American Journal of Hematology|2023Cited by 1
Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)Enrica Antonia Martino, Federico Vozzella, Raffaella Pasquale et al.|Blood|2024Cited by 0